Alto Neuroscience Common Stock Lists on NYSE Under ANRO

TL;DR

**Alto Neuroscience (ANRO) just listed its common stock on the NYSE, boosting visibility and liquidity.**

AI Summary

Alto Neuroscience, Inc. filed an 8-K on February 6, 2024, to report that its common stock, with a par value of $0.0001 per share, is now registered on The New York Stock Exchange under the trading symbol ANRO. This filing indicates a significant step for the company, as listing on a major exchange like the NYSE can increase visibility and liquidity for investors. For current or prospective shareholders, this means easier trading and potentially greater investor interest, which could positively impact the stock's value.

Why It Matters

Listing on the NYSE can enhance Alto Neuroscience's market presence, potentially attracting more institutional and retail investors, which could lead to increased trading volume and a more stable stock price.

Risk Assessment

Risk Level: low — This filing primarily concerns a stock exchange listing, which is a procedural event and generally carries low direct risk to investors.

Analyst Insight

A smart investor would monitor trading volume and institutional ownership trends for ANRO in the coming months, as the NYSE listing could attract new capital and increase market visibility.

Key Numbers

• $0.0001 — Par value per share (The stated par value of Alto Neuroscience's common stock.)

Key Players & Entities

• Alto Neuroscience, Inc. (company) — the registrant whose common stock is now listed on the NYSE
• The New York Stock Exchange (company) — the exchange where Alto Neuroscience's common stock is now registered
• ANRO (company) — the trading symbol for Alto Neuroscience's common stock
• $0.0001 (dollar_amount) — the par value per share of Alto Neuroscience's common stock
• February 6, 2024 (date) — the date of the earliest event reported in the 8-K filing

Forward-Looking Statements

• Alto Neuroscience's stock liquidity will increase due to its NYSE listing. (Alto Neuroscience, Inc.) — high confidence, target: Q2 2024
• The company may see increased institutional investor interest following its NYSE listing. (Alto Neuroscience, Inc.) — medium confidence, target: Q3 2024

FAQ

From the Filing

0001193125-24-025266.txt : 20240206 0001193125-24-025266.hdr.sgml : 20240206 20240206160704 ACCESSION NUMBER: 0001193125-24-025266 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24600265 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 8-K 1 d736911d8k.htm 8-K 8-K false 0001999480 --12-31 0001999480 2024-02-06 2024-02-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024     Alto Neuroscience, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-41944   83-4210124 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos , CA 94022 (Address of principal executive offices) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report.)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amendment and Restatement of Certificate of Incorporation In connection with the closing of the initial public offering of shares of common stock (the “IPO”) of Alto Neuroscience, Inc. (the “Company”), on February 6, 2024, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and s